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Abstract
Background
Treatment for tuberculosis lasts for a minimum of 6 months. The treatment burden experi-
enced by patients in a low-incidence setting where directly observed therapy is the standard
of care is not well-known.
Methods
Patients receiving tuberculosis treatment through the chest clinic at a tertiary hospital in
Sydney, Australia, participated in a semi-structured interview. The interviews explored the
treatment burden experienced by patients and possible solutions to ameliorate this burden.
Interviews were conducted until data saturation was achieved. They were recorded, tran-
scribed and analysed using NVivo 12 software.
Results
Twenty participants (80% male, mean age 40 years) with pulmonary (n = 13) and extra-pul-
monary (n = 7) tuberculosis were interviewed. Participants experienced healthcare, finan-
cial, social and medication burdens along with lifestyle changes due to treatment.
Medication intake was challenging due to the high number of pills, and 55% (n = 11) of
patients experienced fatigue amongst other side effects. Patients found clinic-based directly
observed therapy inconvenient, especially those working and/or studying. Suggestions to
lessen treatment burden included reducing medication burden and better access to health
services.
Conclusion
Tuberculosis treatment is associated with substantial treatment burden for patients. Mea-
sures to reduce treatment burden including alternative treatment delivery methods which
are more accommodating to patients than clinic-based directly observed therapy, such as
video directly observed therapy or partially self -administered treatment, should be consid-
ered on a case-by-case basis.
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Introduction
First-line treatment for drug-sensitive tuberculosis (TB) as outlined by the World Health
Organization (WHO) involves a combination of isoniazid, rifampicin, pyrazinamide and eth-
ambutol for a minimum of 6 months [1]. WHO recommends that these medications are
administered through directly observed therapy (DOT), where patients’ consumption of medi-
cations is observed by trained personnel (usually a healthcare worker) [2]. However, a
Cochrane review concluded that DOT does not improve TB treatment completion and cure
compared with self-administered treatment [3].
Treatment burden is the workload that a patient must manage to take care of their health
and its impact on the patient’s daily life [4]. Examples of treatment burden include scheduling
appointments, travelling to appointments or managing medications. Time-consuming treat-
ments in chronic diseases without adequate support of the patient or communication between
healthcare providers can negatively impact clinical outcomes [5–7]. Medication [8, 9], social
[9, 10] and financial burdens [11] are commonly experienced by patients with TB. Previous
interview studies have demonstrated that there is a ‘pill burden’ caused by the many tablets
that patients must consume and related medication side effects [8, 9]. This burden substan-
tially increases in patients with multi-drug resistant TB with an increased treatment timeframe
(up to 24 months) and the inclusion of injectable medications [12]. Socially, receiving TB treat-
ment (particularly through DOT) can also worsen real or perceived stigma associated with TB,
as patients might fear that people around them will learn about their disease when they know
that they are attending the TB clinic. Patients may therefore avoid visiting treatment clinics
and be reluctant to take medication [10]. Interlinked with medication and social burden is the
impact on a patient’s finances. Patients are required to travel to a central clinic for clinic-based
DOT, which comes at a direct cost to the patient (public transport, fuel, parking etc.) as well as
indirect or opportunity costs (e.g. unpaid leave) [8, 11].
Given the lack of evidence that clinic-based DOT improves TB treatment completion and
cure [3] but anecdotal experience of a significant treatment burden associated with DOT in
our patients, we aimed to explore the treatment burden associated with TB treatment in a low-
incidence setting for TB, where clinic-based and video DOT are commonly used, and to
explore ways to alleviate treatment burden. The gathered data can inform patient-centred
health service delivery and health policies for TB treatment.
Methods
Study design, setting and participants
We used semi-structured interviews to obtain an in-depth understanding of patient experi-
ences of treatment burden associated with TB treatment. The study was conducted at the chest
clinic of Liverpool Hospital in South Western Sydney, New South Wales, Australia, which
serves a multicultural community. The TB incidence rate of 9.02 per 100,000 in this area is one
of the highest in the state of New South Wales which had an incidence of TB of 6.4 per 100,000
in 2018 [13]. In the state of New South Wales, Australia, clinic-based DOT has been the stan-
dard of TB treatment until recently. However, chest clinic nurses deliver treatment to TB
patients in the community while patients are infectious or if they are elderly and impaired. All
TB services (including medications for the disease and for treatment of side-effects) are pro-
vided free of charge, through local chest clinics affiliated with public hospitals [14]. More
recently, accelerated by the COVID-19 pandemic, video DOT (where supervision is delivered
digitally) [15] and a combination of clinic-based DOT (e.g. once every two weeks) and self-
administered therapy (SAT) are increasingly used as alternatives to standalone clinic-based
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DOT. These alternatives provide flexibility and privacy whilst saving time and direct costs to
the patient [16].
Eligible study participants were (1) undergoing DOT, a combination of DOT and SAT or
video DOT for active pulmonary or extra-pulmonary TB, or had completed treatment in the
past 12 months, (2) were at least 18 years of age and (3) could communicate in English without
the need for an interpreter. Potential participants were identified through the chest clinic’s TB
notification records and recruited in the clinic or over the phone. Purposive sampling was
used to recruit patients with different characteristics (age, sex, treatment type and duration).
Participants were provided with a participant information leaflet and written or verbal consent
(for phone interviews) was obtained prior to conducting interviews. Ethical approval for this
study was obtained from the South Western Sydney Local Health District Human Research
and Ethics Committee.
Data collection
A preliminary TB specific treatment burden framework which was informed by a taxonomy of
the burden of treatment [17], a literature review and input from TB experts was used to create
an interview guide specific to this study. This guide was piloted in 3 interviews. A final revised
interview guide was used for all other interviews (S1 File). Interviews were conducted by one
of the investigators (NCHT) until data saturation was achieved. Interviews were performed
either in person (i.e. face-to-face) or over the telephone, both within a clinic room. These were
voice-recorded, transcribed and uploaded into the qualitative analysis software NVivo 12.
Pseudonyms were then assigned to each participant.
Data analysis
A deductive-inductive approach was used to code for themes using NVivo 12. Information
supporting the preliminary framework was searched for and coded into pre-determined cate-
gories (nodes) and sub-categories (sub-nodes) during the first round of narrative coding. New
information not included in the framework was noted and through discussion with study
investigators, new categories were created during the coding process. A second round of cod-
ing was then performed on all interviews to identify themes belonging in the new categories.
The final TB treatment burden framework was created to include updated categories. One of
the investigators (NCHT) coded all interviews. The coding framework was reviewed and
adjusted after the first two interviews by the senior investigator (CCD). Two other investiga-
tors (NET, MSHC) independently coded four randomly selected interview transcripts for qual-
ity assurance purposes. Any differences were discussed and reviewed.
Results
Of 32 patients who initially agreed to be interviewed, three later withdrew and nine could not
be further contacted for an interview. Overall, 20 participants were interviewed with 15 in-per-
son and five phone interviews. Interview times ranged from 18 to 52 minutes, with a mean of
27 minutes. Table 1 summarises patient and treatment characteristics.
Treatment burden discovered
Thirteen types of treatment burden were identified by patients: direct costs, indirect costs,
appointment burden, lack of continuity of care, medical paperwork, travel burden, travel
restrictions, impact on social dynamics, pill burden, medication side effects, adjustment of
work and study, adjustment of sleep and change in dietary and other habits (Table 2). These
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were further summarised under five broad categories of financial burden, healthcare burden,
medication burden, social burden and lifestyle changes. Suggestions made to ameliorate treat-
ment burden were summarised under two categories: better provision of health services and
access, and a less burdensome treatment regimen. The preliminary treatment burden frame-
work was revised based on interview findings and a final framework was produced (Fig 1).
Table 1. Participant information.
Characteristic n %
Gender
Male 16 80
Female 4 20
Age in years
Range 18 to 70
Mean 40 -
Country of birth
Australia 3 15
Bangladesh 1 5
India 4 20
Indonesia 2 10
Myanmar 1 5
Nepal 2 10
Philippines 2 10
Sierra Leone 1 5
Vietnam 3 15
Zimbabwe 1 5
Type of tuberculosis
Pulmonary 13 65
Extra-pulmonary 7 35
Current treatment status
Intensive phase (<2 months) or isolation 9 45
Continuous phase (>2 months) 10 50
Completed treatment 1 5
Employment status
Retired 3 15
Unemployed 2 10
Employed and/or studying 15 75
Form of therapy
Clinic based directly observed therapy 14 70
Video directly observed therapy 5 25
Othera 1 5
Form of transport used to the TB clinic
Public transport 6 30
Car 14 70
Reported number of tablets per daily dosage (excluding completed patient)
Less than 10 tablets 10 52.6
More than 10 tablets 9 47.4
a Patient previously was on clinic-based DOT but moved onto an altered treatment regimen of visiting clinic once-
fortnightly and had 13 days take home supply.
https://doi.org/10.1371/journal.pone.0241124.t001
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Financial burden
Direct costs. Fifteen participants incurred travel costs associated with chest clinic visits.
Parking costs ranged from $0 up to $20 per visit, average petrol costs were an estimated $10
per visit whilst public transport costs ranged from $3 to $7 per visit. Costs depended on dis-
tance to clinic, visitation frequency, type of petrol used and the car model. Some participants
identified these costs as being burdensome. One participant described his health as more
important than financial hardship. Two participants received a fine for parking overtime in a
designated patient parking spot while attending the TB clinic, which added to their financial
burden.
“When they first told me I was gonna [sic] have to go in everyday, yea, that would have been a
nightmare paying for parking and petrol and not being able to work”–Anna, working mother
with young children
Indirect costs. Time taken off work to attend chest clinic DOT resulting in loss of income
affected more than half of participants, with 9 experiencing a financial burden as a result.
Indirect costs affected most working participants regardless of whether they were paid an
hourly salary or were on a fixed income. Those with a fixed salary often had to take more sick
leave to attend appointments than the amount they were entitled to, and therefore lost income
as well.
“When you’re interrupted for 2 hours everyday, it interrupts everything. . .2 hours I cannot
work. . .one fourth of my time. Definitely it affects my income”–Mahir, health professional
Fig 1. Treatment burden framework for tuberculosis. Red: main theme; orange: main categories of treatment burden; yellow: sub-themes; green: specific forms of
treatment burden.
https://doi.org/10.1371/journal.pone.0241124.g001
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Healthcare burden
Appointment burden. Patients visited the chest clinic in person (for DOT or doctor vis-
its) or attended scheduled video appointments for video DOT. Visitation frequency ranged
from daily to thrice weekly; three participants visited less than once a week and one received
community-based DOT through TB clinic staff. Two participants recalled waiting at least an
hour for their doctor appointment.
Frequent appointments were inconvenient and disruptive, causing patients having to rear-
range work and study commitments and forgo social events or travel. Co-ordination between
specialist appointments for different health issues was also a burden, due to limited timeslots
and appointment clashes. Rescheduling appointments often caused further delay.
“Probably the most hardest part of this treatment is to come in. . .you need an extra 3 hours in
the bank to accommodate for this, it gets pretty inconvenient if you have to come every day”–
Amod, student and part-time worker
Lack of continuity of care. Some patients who also saw a specialist for a condition other
than TB experienced a lack of communication between doctors, making their care fragmented.
Medical formalities. Medical work-up (e.g. imaging, blood tests) and paperwork was
sometimes required and a hassle to obtain. Some patients had to wait during prolonged peri-
ods when they required a medical certificate outside of a scheduled doctor’s appointment.
Travel to treatment centre. Patients commonly found travelling to the chest clinic for
DOT inconvenient and time-consuming. A quarter of participants found their return trip
stressful due to medication side effects. For some, daily travel to the TB clinic was very cum-
bersome because they lived far away.
“I literally would have to give up work and even then I’d still be on an hour and a half each
way, that’s 3 hours round. . .so I’ve got to drive and I’ve got to be doing that everyday just to
get medication.”–John, works in sales
Most participants drove to the TB clinic by car and experienced stress with traffic and park-
ing. A small group of participants took public transport and all except one found travel time to
be long or tiresome, with irregular transport schedules adding to this frustration.
“It’s a waste of traffic time, it’s a waste of my time, you’re burning petrol. So I travel 20 min-
utes but I’m not sure [about] people who have to travel longer distances. . .”–Saharsh, recently
commenced DOT
Medication burden
Pill burden. Patients on average had to take 10 tablets per daily dosage. The high number
of tablets and the unpleasant taste made medication consumption difficult. Six participants
found the medications hard to swallow, with one taking up to an hour to swallow his daily
dose. Some required tablets to be crushed or opted for a liquid alternative where possible.
“When there was [sic] 4 drugs, it was a lot, like 16, 17 tablets a day. Just swallowing them is
not an easy task and you still get nauseous after taking them”–Edward, TB patient
Side effects. Participants experienced at least one side effect with fatigue (n = 11) and nau-
sea (n = 9) being most commonly reported. Other side effects included skin rash, heartburn,
PLOS ONE Treatment burden in tuberculosis
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weight loss, loss of appetite, and numbness in arms or legs. Two patients had treatment paused
due to severe side effects and required an adjusted treatment regimen.
“I do have symptoms of nausea and all that, all the time, even with like metoclopramide and
also ondansetron. . .I still feel nauseous”–Isabella, TB patient
Fatigue was the main concern for patients, having an impact on their usual daily routine.
Studying and working participants had to accommodate for the symptom by rearranging
schedules. Participants generally found the side effects of treatment more tolerable as treat-
ment progressed or as the number of tablets decreased over time.
“It really did affect me work wise and studying because if I were to take the medications, I just
automatically become like the zombie. . .in some instances, I’ll just sleep. . .you really do feel
really tired, so tired”–Jerod, student and employed worker
Social burden
Impact on social dynamics. Some patients missed out on social events due to treatment
appointments whilst others found it hard to socialize when they experienced side effects of TB
treatment. Seven participants kept their treatment confidential except for sharing the informa-
tion with close family and friends, and three participants felt stigmatised (e.g. avoided) when
people knew that they were receiving treatment for TB. Four participants avoided contact with
others after their diagnosis, being worried about infecting others.
Travel restrictions. For some, treatment restricted travel interstate or overseas for work
and/or leisure, due to the need to take medications. One participant mentioned that the num-
ber of medications they would have to bring discouraged them from travelling. Other partici-
pants had no issues and did not feel that their treatment regimen restricted their ability to
travel.
Lifestyle changes
Adjustment in work and study. For workers and students, appointments and symptom
management impacted on productivity levels. Students experienced difficulties in managing
classes and study time, whilst workers experienced disruptions to work commitments. One
patient felt burdensome to his colleagues as they were required to work around his treatment
schedule.
“I had to go to the hospital every day, it was a bit challenging because I had to go to the hospi-
tal first and then go to work, and it had a significant impact on my work because it was quite
stressful because both are equally important. . .”—Nandin, full-time worker
Adjustment in sleep. Five participants changed their sleeping patterns to accommodate
for fatigue. Four patients went to bed earlier to minimise the amount of fatigue felt after medi-
cation consumption. One patient mentioned that sleeping earlier also meant being able to
wake early enough to fit in medications before work.
Changes in habits. Most participants changed their eating schedule (fasting an hour
before and after medications, as instructed) and diet. Of those who smoked, one continued
smoking at a reduced amount whilst all others quit. Fatigue resulted in a reduced ability to
exercise in some patients.
PLOS ONE Treatment burden in tuberculosis
PLOS ONE | https://doi.org/10.1371/journal.pone.0241124 October 22, 2020 8 / 13
Video DOT
Video DOT patients preferred video DOT over clinic-based DOT, having found it convenient
and very accessible. The video phone application was easy to learn and connection was gener-
ally good; one participant occasionally experienced slow connectivity.
“Coming every day to the hospital is definitely more difficult than learning to connect to a con-
ference on whatever a laptop, tablet. I mean, it’s pretty flexible to you, you just need an elec-
tronic device”–Joseph, student
Half the video DOT patients mentioned that the fixed video appointment time was still
hard to meet especially during work hours. Medication storage and organization at home was
not an issue.
Reducing treatment burden
Patients suggested two ways to reduce treatment burden: (1) better provision of health services
and access and (2) a less burdensome treatment regimen.
Better provision of health services and access. Patients suggested improved access to
medical assistance such as a direct line to a doctor when quick TB medical advice was required
between scheduled doctor appointments. Some requested that chest clinic nurses were able to
write medical certificates, instead of waiting for a scheduled doctor’s appointment. Other par-
ticipants recommended more facilities for DOT (e.g. local GP) to reduce travel times. Having
extended chest clinic hours was another suggestion to accommodate for those who had to
work during opening hours.
Education was suggested to better equip patients for changes that treatment would have on
their lifestyle and to inform society that TB is non-contagious when treated, to reduce social
isolation of patients.
Less burdensome treatment regimens. Patients frequently suggested making medica-
tions easier to consume. Suggestions included reducing tablet size and number or introducing
more liquid options. A participant on a combination of DOT and SAT found half tablets in his
treatment regimen challenging, at times becoming confused about the number of tablets he
was taking.
Two participants with multi-drug resistant TB suggested having a shorter treatment period.
Three participants, two on video DOT and one on DOT, suggested recording medication con-
sumption to be viewed by nurses later, such that direct observation is not in real-time. This
would allow patients to complete treatment when free, rather than taking time out from work
or study.
Nearly half (n = 9) of interviewees stated that SAT, either for part or all of treatment, would
make treatment easier. Two participants did not support SAT, believing DOT is necessary to
maintain compliance with treatment.
Discussion
This study is the first to explore patient-perceived treatment burden in TB in a country with a
low-incidence of TB where standard treatment involves clinic-based DOT and video DOT.
This study has highlighted the substantial amount of time and effort required from TB patients
to manage their treatment, similar to the treatment burden previously described in chronic
conditions such as cystic fibrosis [18] and chronic obstructive pulmonary disease [19]. Partici-
pants described various forms of treatment burden (Fig 1) with the majority related to DOT
and medication taking. Treatment burden had a significant impact on participants’ daily life
PLOS ONE Treatment burden in tuberculosis
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and although many struggled with adjusting to a lengthy and time-consuming treatment regi-
men, most understood the importance of treatment completion.
Clinic-based DOT was physically and mentally draining to some patients. Key burdens
included adjustment to personal life, work or study and direct and indirect costs, consistent
with findings from a cross-sectional questionnaire study in Singapore [20] Some patients
would have given up treatment if their regimen had not been altered from strict clinic-based
DOT to include a combination of DOT and SAT, highlighting the high treatment burden asso-
ciated with DOT. Importantly, DOT has not been shown to improve adherence to TB treat-
ment or TB cure rates compared with SAT in a systematic review, when patients on SAT
visited the TB clinic at least every 2 weeks [3].
An attempt to lower treatment burden and clinic non-attendance in countries with a high
incidence of TB has given rise to community-based DOT—DOT provided in the community
by community health care workers or community volunteers [21]. Patients find it more conve-
nient, as treatment is delivered directly to their home and community healthcare providers are
able to personally follow-up on delayed or missed doses [22].
Video DOT was positively regarded by most patients in this study. In other studies, treat-
ment completion rates have been shown to be similar for video DOT and clinic-based DOT
[23]. Video DOT provides flexibility and privacy to the patient, whilst saving time and direct
costs [16]. The privacy aspect was important to patients who believed there to be perceived
stigma about TB and were not comfortable being seen going to chest clinic. However, it
requires a real-time cellular connection and is only feasible if patients have access to a suitable
device and stable internet connection. Additionally, the nurses in our study setting reported
that video DOT was more time consuming for them (as it required time to set up and some-
times required troubleshooting digital issues) than clinic-based DOT. Video DOT can be
made more flexible for patients and health professionals by removing real-time direct observa-
tion, as suggested by several participants in our study. This method of video DOT, asynchro-
nous video DOT, involves time-delayed observation of medication consumption through
video uploads [24].
Difficulties with medication intake due to number or size of pills were another key burden
identified, reflecting findings consistent with previous interview studies [8, 9]. In chronic con-
ditions such as diabetes, fixed drug combination therapies have been found to improve patient
satisfaction by combining multiple tablets into one, improving adherence to treatment [25].
Fixed drug combination therapy has been recommended by WHO for TB since 2001 through
the combination of 2 to 4 anti-TB drugs [26]. Since then, several countries have adopted fixed
drug combinations for TB treatment. However, these are not as flexible when patient-specific
formulations are required, and the inseparable nature of the pill makes it difficult to determine
the source of potential adverse effects. An increase in patient satisfaction when using fixed
drug combinations has, however, been identified and the use of fixed dose combination ther-
apy should be considered on a case-by-case basis, especially in those who struggle with swal-
lowing tablets.
Alongside pill burden, treatment side effects had a significant impact on many patients,
with some requiring extra medications to alleviate symptoms caused as a side effect of TB
treatment, adding to their pill burden. Fatigue reduced quality of life and affected work and
study. Fatigue was a substantial burden to many participants as it could not be alleviated by
taking remedial medications. Patients who self-administered their medications at home had
option to take the medications close to bedtime to alleviate the impact of fatigue on quality of
life.
Some interviewees felt uncomfortable and stigmatised when attending the chest clinic for
treatment. This, however, did not negatively impact treatment adherence in these interviewees,
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as described in a qualitative study in a high TB incidence setting [10]. Stigma is not just experi-
enced by TB patients in settings with a high incidence of TB but also by patients in settings
with a low incidence of TB [27], although the reasons might differ (e.g., TB may be linked to
evil spirits in high incidence settings [28], whereas in low incidence setting stigma may be
mainly the result of TB patients being considered infectious [even if they are not] [8] as experi-
enced by some of our patients). Stigma can potentially be minimised through TB treatment
delivery that is more private and flexible to patients, as previously discussed.
A strength of this study was the use of an iterative approach to allow interviews to be
adapted in response to emergent themes. The semi-structured style of interviewing allowed
participants to freely share their experiences. The study was conducted in a high-income coun-
try with a low TB incidence and findings from this study may not necessarily apply to low-
income, high-incidence settings. However, although the severity of different areas of treatment
burden may vary, most of the challenges experienced by our study participants will likely be
similar across settings (e.g. loss of income due to treatment requirements) and probably more
accentuated in low-income settings. It is possible that participants who agreed to an interview
may have experienced more hardships with their treatment and thus were more willing to
voice their dissatisfactions compared with patients who did not participate in the study.
Conclusions
Our study highlights the substantial treatment burden associated with TB treatment, particu-
larly with clinic-based DOT. Health providers should be aware of their patients’ capacity to
handle treatment workload and that different burdens have different significance for individ-
ual patients. Measures to ameliorate the treatment burden include changes in treatment deliv-
ery on a case-by-case basis (for example, using approaches that combine DOT with self-
administered therapy, video DOT (including asynchronous video DOT) and community-
based DOT), providing better access to health services and improving patient education
(before treatment is commenced) about the potential impact of TB treatment on patient’s
everyday life. Development of a community-based DOT model using community workers or
trained lay workers could potentially reduce patients’ treatment burden without overstretching
health system resources.
In settings with a significant proportion of patients who prematurely cease TB treatment,
research into the burden of treatment experienced by these patients may offer insights on how
to improve health services to make them more patient-centred.
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